Pelthos Therapeutics posts investor deck outlining dermatology portfolio strategy centered on Zelsuvmi launch, Xepi and Xeglyze additions

• Pelthos highlighted commercial traction for Zelsuvmi, with more than 20,000 units dispensed since the July 2025 launch through April 2026.
• Portfolio expansion centered on two FDA-approved dermatology assets, Xepi for impetigo and Xeglyze for head lice, to leverage existing infrastructure.
• Xepi relaunch targeted for Q1 2027; Xeglyze commercial launch planned for Q3 2027.
• Key equity metrics as of 08/10/26: stock price $29; about 9,000,000 shares outstanding; market cap about $260 million.
• Cash at end of Q2 2026 totaled $24.2 million; 60-day average daily trading volume about 51,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.